Itolizumab in addressing symptoms of acute respiratory distress syndrome (ARDS) with weaning off oxygen requirements in a COVID-19 patient: A case study


Case Report

Author Details : Hemant P Thacker*, Amit Dhekane, Nivedita Wadhwa, Shalaka Patil

Volume : 6, Issue : 1, Year : 2021

Article Page : 58-61

https://doi.org/10.18231/j.ijirm.2021.013



Suggest article by email

Abstract

Hyperinflammation and cytokine storm have been reported in severe coronavirus disease (COVID-19) patients. Persistent elevated levels of inflammatory cytokines may lead to an increased risk of vascular hyperpermeability, multiorgan failure, and eventually death over time. Repurposed Itolizumab, a humanized recombinant anti-CD6 monoclonal antibody, is found to inhibit T-cell proliferation and reduce IFN-g , IL-6, and TNF-a production, thereby leading to reduction in the T-cell infiltration at the sites of
inflammation. Here we report a case of a 69 year old COVID-19 confirmed male patient who presented with a history of fever, cough and fatigue. The patient had elevated levels of serum ferritin and CRP. His SpO2 was 80% and ground glass opacities were observed in his chest X-ray. The patient was initiated on oxygen (using HFR mask) along with best supportive care and saturation was maintained at SpO2 of 85%. Itolizumab (1.6 mg/kg) was administered as an intravenous infusion (Day 1). On Days 3 and
4, the patient continued on oxygen and maintained a SpO2 90% - 92%. On Day 7, there was a 87.86% reduction in the inflammatory marker CRP from baseline. On Day 8, the patient was off oxygen. On Day 9, there was further clinical improvement and the chest x-ray revealed reduction of opacities at the basal and hilar regions. Day 10 showed further CRP reduction of 97.69% from baseline. On Day 12, the patient was discharged. Itolizumab, along with best supportive care, shows potential to reduce hyperinflammation leading to clinical and radiological improvement in COVID-19 patients with severe disease.

Keywords: Acute respiratory distress syndrome, Anti CD6 humanised monoclonal antibody, Cytokines, Cytokine storm, Hyperinflammation, Itolizumab, COVID-19.


How to cite : Thacker H P, Dhekane A , Wadhwa N , Patil S , Itolizumab in addressing symptoms of acute respiratory distress syndrome (ARDS) with weaning off oxygen requirements in a COVID-19 patient: A case study. IP Indian J Immunol Respir Med 2021;6(1):58-61


Copyright © 2021 by author(s) and IP Indian J Immunol Respir Med. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)



View Article

PDF File   Full Text Article


Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijirm.2021.013


Article Metrics






Article Access statistics

Viewed: 259

PDF Downloaded: 112